Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCCG-APL-2017 childhood APL trial
ChiCTR-OIC-16010014Phase 4Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Nov 2016
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, single-arm trial of Compound Huangdai Tablet in Acute promyelocytic leukaemia (APL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Bone marrow morphology, Bone marrow fusion gene test and 2 more. Started Nov 2016; status: completed.
02
Drugs
Compound Huangdai Tablet
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ChiCTR-OIC-16010014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16010014.